CN1533388A - 取代的哌嗪化合物及其作为脂肪酸氧化抑制剂的应用 - Google Patents

取代的哌嗪化合物及其作为脂肪酸氧化抑制剂的应用 Download PDF

Info

Publication number
CN1533388A
CN1533388A CNA02814371XA CN02814371A CN1533388A CN 1533388 A CN1533388 A CN 1533388A CN A02814371X A CNA02814371X A CN A02814371XA CN 02814371 A CN02814371 A CN 02814371A CN 1533388 A CN1533388 A CN 1533388A
Authority
CN
China
Prior art keywords
methyl
propan
phenyl
formula
base
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA02814371XA
Other languages
English (en)
Chinese (zh)
Inventor
���˹�����ײ�˹
普拉巴·易卜拉欣
凯文·申克
�ٺա���������
埃尔法蒂赫·埃尔扎因
文卡塔·帕勒
�����ִĻ�
杰夫·扎布沃茨基
肯尼思·雷德尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Palo Alto Inc
Original Assignee
CV Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CV Therapeutics Inc filed Critical CV Therapeutics Inc
Publication of CN1533388A publication Critical patent/CN1533388A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Lubricants (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Paper (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
CNA02814371XA 2001-07-19 2002-07-18 取代的哌嗪化合物及其作为脂肪酸氧化抑制剂的应用 Pending CN1533388A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30662101P 2001-07-19 2001-07-19
US60/306,621 2001-07-19

Publications (1)

Publication Number Publication Date
CN1533388A true CN1533388A (zh) 2004-09-29

Family

ID=23186103

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA02814371XA Pending CN1533388A (zh) 2001-07-19 2002-07-18 取代的哌嗪化合物及其作为脂肪酸氧化抑制剂的应用

Country Status (21)

Country Link
US (1) US6930111B2 (OSRAM)
EP (1) EP1406898B1 (OSRAM)
JP (1) JP2004537554A (OSRAM)
KR (1) KR100919141B1 (OSRAM)
CN (1) CN1533388A (OSRAM)
AT (1) ATE292633T1 (OSRAM)
AU (1) AU2008202958A1 (OSRAM)
CA (1) CA2454059A1 (OSRAM)
DE (1) DE60203623T2 (OSRAM)
DK (1) DK1406898T3 (OSRAM)
ES (1) ES2236557T3 (OSRAM)
HU (1) HUP0402088A3 (OSRAM)
IL (1) IL159897A0 (OSRAM)
MX (1) MXPA04000565A (OSRAM)
NO (1) NO327635B1 (OSRAM)
NZ (1) NZ530705A (OSRAM)
PL (1) PL368529A1 (OSRAM)
PT (1) PT1406898E (OSRAM)
RU (1) RU2300533C2 (OSRAM)
WO (1) WO2003008411A1 (OSRAM)
ZA (1) ZA200400404B (OSRAM)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101981015A (zh) * 2008-03-31 2011-02-23 霍夫曼-拉罗奇有限公司 作为hdl-胆固醇升高剂的3-三氟甲基-吡嗪-2-甲酸酰胺衍生物
CN111285819A (zh) * 2018-12-07 2020-06-16 江苏恩华药业股份有限公司 一种苯并噁唑类化合物及其应用

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7001909B2 (en) * 2001-07-19 2006-02-21 Cv Therapeutics, Inc. Substituted heterocyclic compounds
CA2486712C (en) * 2002-05-21 2012-01-03 Cv Therapeutics, Inc. Method of treating diabetes
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
EP1581525A2 (en) * 2002-08-09 2005-10-05 AstraZeneca AB Compounds having an activity at metabotropic glutamate receptors
IL166510A0 (en) 2002-08-09 2006-01-15 Nps Pharma Inc 1,2,4"oxadiazole as modulators of metabotropic glutamate receptor-5
JP2006506340A (ja) * 2002-08-09 2006-02-23 アストラゼネカ アクチボラグ 代謝調節型グルタミン酸受容体５のモジュレーターとしてのオキサジアゾール
EP1806346B1 (en) * 2002-12-05 2009-07-22 Cv Therapeutics, Inc. Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
DE60328545D1 (de) * 2002-12-05 2009-09-03 Cv Therapeutics Inc Substituierte Piperazinderivate und ihre Verwendung als Inhibitoren der Fettsäureoxidation
AU2003303676A1 (en) 2003-01-03 2004-08-10 Gilead Palo Alto, Inc. Substituted heterocyclic compounds
KR20050092424A (ko) * 2003-01-17 2005-09-21 씨브이 쎄러퓨틱스, 인코포레이티드 심혈관 질환의 치료에 유용한 치환된 헤테로고리 화합물
AU2004252102A1 (en) * 2003-06-23 2005-01-06 Gilead Palo Alto, Inc. Urea derivatives of piperazines and piperidines as fatty acid oxidation inhibitors
WO2005061470A1 (en) * 2003-12-18 2005-07-07 Cv Therapeutics, Inc. 1-akan-2-ol substituted piperazine and piperidine compounds
JP2007517550A (ja) * 2004-01-02 2007-07-05 アドヴァンスド カーディオヴァスキュラー システムズ， インコーポレイテッド 高比重リポ蛋白をコーティングした医療デバイス
KR20070051305A (ko) * 2004-09-08 2007-05-17 씨브이 쎄러퓨틱스, 인코포레이티드 치환된 피페라진 화합물 및 지방산 산화 저해제로서의 이의용도
EP2056844A4 (en) 2006-08-24 2010-11-24 Wockhardt Research Center NEW MACROLIDS AND KETOLIDS WITH ANTIMICROBIAL EFFECT
EP3135672B9 (en) 2008-10-10 2020-05-20 VM Discovery, Inc. Compositions and methods for treating alcohol use disorders, pain and other diseases
WO2010132696A1 (en) * 2009-05-14 2010-11-18 Gilead Palo Alto, Inc. Ranolazine for the treatment of cns disorders
WO2011115150A1 (ja) * 2010-03-18 2011-09-22 興和株式会社 ベンゾチアジン化合物の製造方法
WO2023023995A1 (zh) * 2021-08-25 2023-03-02 苏州大学 一种防治心肌缺血后心功能衰竭的药物及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1133989A (en) 1964-12-08 1968-11-20 Chugai Pharmaceutical Co Ltd Theophylline derivatives, their salts and process for preparing the same
DE2834114A1 (de) * 1978-08-01 1980-02-14 Schering Ag Polyalkoxyphenylpyrrolidone iii, verfahren zu ihrer herstellung und ihre verwendung
US4567264A (en) * 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
JPS6137765A (ja) * 1984-07-19 1986-02-22 サンド・アクチエンゲゼルシヤフト ３‐アミノプロポキシアリール誘導体
US4723014A (en) * 1986-11-19 1988-02-02 Warner-Lambert Company Process for the preparation of 2-substituted-1,4-dihydropyridines
DE3723648A1 (de) * 1987-07-17 1989-01-26 Sandoz Ag Indol-derivate, ihre herstellung und sie enthaltende arzneimittel
JPH0699399B2 (ja) * 1988-10-06 1994-12-07 三井東圧化学株式会社 新規複素環化合物およびそれを有効成分として含有する製癌剤効果増強剤
JPH02268162A (ja) * 1989-04-10 1990-11-01 Fujisawa Pharmaceut Co Ltd ジフェニルピリジン誘導体
MX9308025A (es) * 1992-12-22 1994-08-31 Lilly Co Eli Compuestos inhibidores de la proteasa del virus dela inmunodeficiencia humana, procedimiento para supreparacion y formulacion farmaceutica que los contiene.
WO1998021190A1 (en) * 1996-11-14 1998-05-22 American Home Products Corporation Substituted tetrahydro-1,3,5-triazin-2[1h]-thiones as anti-atherosclerotic agents
WO2001019839A1 (en) * 1999-09-13 2001-03-22 American Home Products Corporation Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-1-[4-(2-amin-1-yl-ethoxy)-benzyl]-1h-indol-5-ols
SE9904765D0 (sv) 1999-12-23 1999-12-23 Astra Ab Pharmaceutically-useful compounds
AU2001238590A1 (en) 2000-02-22 2001-09-03 Cv Therapeutics, Inc. Substituted piperazine compounds
WO2001062711A2 (en) * 2000-02-22 2001-08-30 Cv Therapeutics, Inc. Substituted alkylene diamine compounds
US6552023B2 (en) 2000-02-22 2003-04-22 Cv Therapeutics, Inc. Aralkyl substituted piperazine compounds
WO2001062744A2 (en) * 2000-02-22 2001-08-30 Cv Therapeutics, Inc. Substituted piperazine compounds
US6451798B2 (en) 2000-02-22 2002-09-17 Cv Therapeutics, Inc. Substituted alkyl piperazine derivatives
SE0003795D0 (sv) * 2000-10-20 2000-10-20 Astrazeneca Ab Pharmaceutically useful compounds
US6573264B1 (en) 2000-10-23 2003-06-03 Cv Therapeutics, Inc. Heteroaryl alkyl piperazine derivatives

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101981015A (zh) * 2008-03-31 2011-02-23 霍夫曼-拉罗奇有限公司 作为hdl-胆固醇升高剂的3-三氟甲基-吡嗪-2-甲酸酰胺衍生物
CN101981015B (zh) * 2008-03-31 2013-08-21 霍夫曼-拉罗奇有限公司 作为hdl-胆固醇升高剂的3-三氟甲基-吡嗪-2-甲酸酰胺衍生物
CN111285819A (zh) * 2018-12-07 2020-06-16 江苏恩华药业股份有限公司 一种苯并噁唑类化合物及其应用

Also Published As

Publication number Publication date
EP1406898B1 (en) 2005-04-06
HUP0402088A3 (en) 2010-03-29
DE60203623T2 (de) 2006-01-19
RU2300533C2 (ru) 2007-06-10
HK1064374A1 (en) 2005-01-28
US6930111B2 (en) 2005-08-16
PT1406898E (pt) 2005-08-31
MXPA04000565A (es) 2005-06-17
AU2002322527B2 (en) 2008-04-17
ATE292633T1 (de) 2005-04-15
CA2454059A1 (en) 2003-01-30
JP2004537554A (ja) 2004-12-16
KR100919141B1 (ko) 2009-09-25
ZA200400404B (en) 2004-10-14
WO2003008411A1 (en) 2003-01-30
DE60203623D1 (de) 2005-05-12
US20030181352A1 (en) 2003-09-25
DK1406898T3 (da) 2005-05-30
KR20040029374A (ko) 2004-04-06
NO20040234L (no) 2004-03-18
NO327635B1 (no) 2009-09-07
EP1406898A1 (en) 2004-04-14
NZ530705A (en) 2005-08-26
IL159897A0 (en) 2004-06-20
AU2002322527A2 (en) 2003-03-03
AU2008202958A1 (en) 2008-07-31
ES2236557T3 (es) 2005-07-16
PL368529A1 (en) 2005-04-04
RU2004104951A (ru) 2005-06-27
HUP0402088A2 (hu) 2005-02-28

Similar Documents

Publication Publication Date Title
CN1533388A (zh) 取代的哌嗪化合物及其作为脂肪酸氧化抑制剂的应用
CN1293076C (zh) 过氧化物酶体增殖剂应答性受体δ的活化剂
CN1028991C (zh) 四氢化萘衍生物的制备方法
CN1221548C (zh) 含有砜亚氨基官能团的噁唑烷酮
CN1556805A (zh) 作为nmda受体拮抗剂的哌啶衍生物
CN1321152A (zh) 作为hPPARγ和hPPARα激活剂的取代的噁唑和噻唑衍生物
CN1649853A (zh) 噻唑烷酮类化合物、其制备方法以及作为药物的应用
CN1675189A (zh) 苯并噻唑衍生物的新用途
CN1642927A (zh) 环状酰胺
CN101039937A (zh) 在呼吸系统疾病的治疗中用作β模拟剂的杂芳基化合物
CN1652780A (zh) 可以用作cdk4选择性抑制剂的二氨基噻唑类化合物
CN1522253A (zh) 新颖的杂环衍生物及其医疗用途
CN1610675A (zh) 苯并噻唑－和苯并噁唑－4,7－二酮衍生物及其作为cdc25磷酸酯酶抑制剂的用途
CN1976927A (zh) 新型喹啉噻唑啉酮化合物
CN1108456A (zh) 苯并噻唑化合物及其制法和用途
US7001909B2 (en) Substituted heterocyclic compounds
US7056924B2 (en) Substituted heterocyclic compounds
AU2002322527C1 (en) Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
AU2002322527A1 (en) Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
HK1064374B (en) Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
CN1882337A (zh) 取代的氧杂二唑烷二酮als pai－1抑制剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20040929